FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2921259698> ?p ?o ?g. }

• W2921259698 endingPage "438" @default.
• W2921259698 startingPage "428" @default.
• W2921259698 abstract "Background Iron from haemolysed blood is implicated in secondary injury after intracerebral haemorrhage. We aimed to assess the safety of the iron chelator deferoxamine mesylate in patients with intracerebral haemorrhage and to establish whether the drug merits investigation in a phase 3 trial. Methods We did a multicentre, futility-design, randomised, placebo-controlled, double-blind, phase 2 trial at 40 hospitals in Canada and the USA. Adults aged 18–80 years with primary, spontaneous, supratentorial intracerebral haemorrhage were randomly assigned (1:1) to receive deferoxamine mesylate (32 mg/kg per day) or placebo (saline) infusions for 3 consecutive days within 24 h of haemorrhage onset. Randomisation was done via a web-based trial-management system centrally in real time, and treatment allocation was concealed from both participants and investigators. The primary outcome was good clinical outcome, which was defined as a modified Rankin Scale score of 0–2 at day 90. We did a futility analysis: if the 90% upper confidence bound of the absolute risk difference between the two groups in the proportion of participants with a good clinical outcome was less than 12% in favour of deferoxamine mesylate, then to move to a phase 3 efficacy trial would be futile. Primary outcome and safety data were analysed in the modified intention-to-treat population, comprising only participants in whom the study infusions were initiated. This trial is registered with ClinicalTrials.gov, number NCT02175225, and is completed. Findings We recruited 294 participants between Nov 23, 2014, and Nov 10, 2017. The modified intention-to-treat population consisted of 144 patients assigned to the deferoxamine mesylate group and 147 assigned to the placebo group. At day 90, among patients with available data for the primary outcome, 48 (34%) of 140 participants in the deferoxamine mesylate group, and 47 (33%) of 143 patients in the placebo group, had modified Rankin Scale scores of 0–2 (adjusted absolute risk difference 0·6% [90% upper confidence bound 6·8%]). By day 90, 70 serious adverse events were reported in 39 (27%) of 144 patients in the deferoxamine mesylate group, and 78 serious adverse events were reported in 49 (33%) of 147 patients in the placebo group. Ten (7%) participants in the deferoxamine mesylate and 11 (7%) in the placebo group died. None of the deaths were judged to be treatment related. Interpretation Deferoxamine mesylate was safe. However, the primary result showed that further study of the efficacy of deferoxamine mesylate with anticipation that the drug would significantly improve the chance of good clinical outcome (ie, mRS score of 0–2) at day 90 would be futile. Funding US National Institutes of Health and US National Institute of Neurological Disorders and Stroke." @default.
• W2921259698 created "2019-03-22" @default.
• W2921259698 creator A5000214688 @default.
• W2921259698 creator A5000426332 @default.
• W2921259698 creator A5000437279 @default.
• W2921259698 creator A5000826328 @default.
• W2921259698 creator A5000848787 @default.
• W2921259698 creator A5001697595 @default.
• W2921259698 creator A5001893551 @default.
• W2921259698 creator A5002815959 @default.
• W2921259698 creator A5003394099 @default.
• W2921259698 creator A5006556097 @default.
• W2921259698 creator A5006607050 @default.
• W2921259698 creator A5008112881 @default.
• W2921259698 creator A5008639808 @default.
• W2921259698 creator A5009512368 @default.
• W2921259698 creator A5009623049 @default.
• W2921259698 creator A5009868141 @default.
• W2921259698 creator A5010042773 @default.
• W2921259698 creator A5010577739 @default.
• W2921259698 creator A5010682361 @default.
• W2921259698 creator A5011755884 @default.
• W2921259698 creator A5013038853 @default.
• W2921259698 creator A5014227075 @default.
• W2921259698 creator A5014407076 @default.
• W2921259698 creator A5015766352 @default.
• W2921259698 creator A5017002382 @default.
• W2921259698 creator A5017463095 @default.
• W2921259698 creator A5018029238 @default.
• W2921259698 creator A5018865288 @default.
• W2921259698 creator A5020420078 @default.
• W2921259698 creator A5021789294 @default.
• W2921259698 creator A5022336581 @default.
• W2921259698 creator A5024037134 @default.
• W2921259698 creator A5024312877 @default.
• W2921259698 creator A5025571618 @default.
• W2921259698 creator A5026389928 @default.
• W2921259698 creator A5026954755 @default.
• W2921259698 creator A5028828393 @default.
• W2921259698 creator A5029360210 @default.
• W2921259698 creator A5030665713 @default.
• W2921259698 creator A5032344461 @default.
• W2921259698 creator A5033233067 @default.
• W2921259698 creator A5033252387 @default.
• W2921259698 creator A5035901697 @default.
• W2921259698 creator A5036852575 @default.
• W2921259698 creator A5037076906 @default.
• W2921259698 creator A5038312056 @default.
• W2921259698 creator A5038590177 @default.
• W2921259698 creator A5038918342 @default.
• W2921259698 creator A5039499725 @default.
• W2921259698 creator A5040049224 @default.
• W2921259698 creator A5040753355 @default.
• W2921259698 creator A5041696104 @default.
• W2921259698 creator A5045439266 @default.
• W2921259698 creator A5046585516 @default.
• W2921259698 creator A5048985261 @default.
• W2921259698 creator A5050126514 @default.
• W2921259698 creator A5050182171 @default.
• W2921259698 creator A5052048369 @default.
• W2921259698 creator A5052668764 @default.
• W2921259698 creator A5052768521 @default.
• W2921259698 creator A5054333349 @default.
• W2921259698 creator A5055077849 @default.
• W2921259698 creator A5056211885 @default.
• W2921259698 creator A5056529805 @default.
• W2921259698 creator A5056571328 @default.
• W2921259698 creator A5059453632 @default.
• W2921259698 creator A5060472176 @default.
• W2921259698 creator A5061154632 @default.
• W2921259698 creator A5062421806 @default.
• W2921259698 creator A5063509357 @default.
• W2921259698 creator A5064421474 @default.
• W2921259698 creator A5066321093 @default.
• W2921259698 creator A5067772900 @default.
• W2921259698 creator A5068521659 @default.
• W2921259698 creator A5070919684 @default.
• W2921259698 creator A5072150276 @default.
• W2921259698 creator A5075650737 @default.
• W2921259698 creator A5079153413 @default.
• W2921259698 creator A5083629600 @default.
• W2921259698 creator A5084475391 @default.
• W2921259698 creator A5085455065 @default.
• W2921259698 creator A5086000124 @default.
• W2921259698 creator A5091314623 @default.
• W2921259698 creator A5091890303 @default.
• W2921259698 date "2019-05-01" @default.
• W2921259698 modified "2023-10-17" @default.
• W2921259698 title "Deferoxamine mesylate in patients with intracerebral haemorrhage (i-DEF): a multicentre, randomised, placebo-controlled, double-blind phase 2 trial" @default.
• W2921259698 cites W1485177753 @default.
• W2921259698 cites W185304927 @default.
• W2921259698 cites W1947113872 @default.
• W2921259698 cites W1965893111 @default.
• W2921259698 cites W1990282151 @default.
• W2921259698 cites W1995567109 @default.
• W2921259698 cites W2021648195 @default.
• W2921259698 cites W2022400647 @default.
• W2921259698 cites W2030529426 @default.

• next